antithrombin iii (human) (thrombate iii) Report issue

Biological Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank

Active Ingredient History

NOW
  • Now
Antithrombin (AT) is a small glycoprotein that inactivates several enzymes of the coagulation system. It is a 464-amino-acid protein produced by the liver. It contains three disulfide bonds and a total of four possible glycosylation sites. α-Antithrombin is the dominant form of antithrombin found in blood plasma and has an oligosaccharide occupying each of its four glycosylation sites. A single glycosylation site remains consistently un-occupied in the minor form of antithrombin, β-antithrombin. Its activity is increased manyfold by the anticoagulant drug heparin, which enhances the binding of antithrombin to factor IIa (thrombin) and factor Xa.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

antithrombin alfa | antithrombin iii | antithrombin iii human | antithrombin iii (human) | antithrombin iii,human | antithrombin iii, human | antithrombin iii human plasma-derived | at iii | at-iii | heparin cofactor b | human anti-thrombin-iii | human antithrombin iii | kybernin | npb-06 | thrombate iii

Organizations (33)

Research & Development (33)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (28)

Approved Indications (1)


 

Thromboembolism (approved 1991)

Experimental Indications - Clinical Trial Phases 1-4 (28)


 

Acute Coronary Syndrome (Phase 4)

Antithrombin III Deficiency (Phase 4)

Aortic Valve Insufficiency (Phase 4)

Aortic Valve Stenosis (Phase 4)

Blood Coagulation (Phase 3)

Cardiopulmonary Bypass (Phase 3)

Coronary Artery Bypass (Phase 2)

COVID-19 (Phase 2)

Deficiency Diseases (Phase 2)

Disseminated Intravascular Coagulation (Phase 2)

Drugs, Investigational (Phase 1)

Extracorporeal Membrane Oxygenation (Phase 3)

Healthy Volunteers (Phase 1)

Heart Defects, Congenital (Phase 1)

Hemophilia A (Phase 3)

Hepatic Veno-Occlusive Disease (Phase 2)

Liver Cirrhosis (Phase 1)

Mitral Valve Insufficiency (Phase 4)

Mitral Valve Stenosis (Phase 4)

Neonatology (Phase 4)

Postoperative Hemorrhage (Phase 1)

Pre-Eclampsia (Phase 3)

Reperfusion Injury (Phase 2)

Thoracic Surgery (Phase 2)

Thromboembolism (Phase 2)

Thrombosis (Phase 3)

Traumatology (Phase 2)

Venous Thromboembolism (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 33
  • # of Trial Organizations: 33

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue